Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

clopidogrel

- PMLiVE

Sanofi/Sobi’s haemophilia A therapy shows ‘highly effective’ bleed protection in children

The rare bleeding disorder affects approximately one in every 5,000 male births annually

- PMLiVE

Sanofi/Regeneron’s Dupixent shows significant improvements in paediatric eosinophilic oesophagitis

The chronic inflammatory disease affects approximately one in 2,000 people in the US

- PMLiVE

Sanofi’s investigational frexalimab shows promise in relapsing MS study

Approximately 2.9 million people worldwide are affected by the neurological disease

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EMA for uncontrolled COPD in adults

Approximately 220,000 COPD patients in the EU could be eligible for Dupixent treatment

- PMLiVE

Sanofi and Belharra Therapeutics enter $700m immunological disease collaboration

The partnership will utilise Belharra’s platform to identify and advance small molecules against immunology targets

- PMLiVE

Sanofi/Regeneron’s Kevzara approved by FDA for polyarticular juvenile idiopathic arthritis

The chronic disease is designated as one of the three major types of juvenile idiopathic arthritis

- PMLiVE

Sanofi shares positive late-stage results for Sarclisa in newly diagnosed multiple myeloma

More than 180,000 new cases of the haematological malignancy are diagnosed globally every year

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for uncontrolled COPD

No new treatment approaches have been approved for the respiratory disease in more than a decade

- PMLiVE

Sanofi’s multiple myeloma treatment Sarclisa accepted for FDA priority review

The second most common haematologic malignancy is responsible for more than 180,000 new global diagnoses every year

- PMLiVE

Sanofi, Formation Bio and OpenAI announce AI collaboration to accelerate drug development

The companies will combine data, software and tuned models to bring new medicines to patients more efficiently

- PMLiVE

Sanofi and Regeneron share positive late-stage results for Dupixent in COPD

About 300,000 people in the US have uncontrolled COPD and evidence of type 2 inflammation

- PMLiVE

Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A

The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links